FLJ31485 Inhibitors
FLJ31485 inhibitors are not defined by a specific chemical class, instead, they encompass a diverse range of compounds that influence various cellular pathways which could indirectly lead to the inhibition of FLJ31485. For instance, kinase inhibitors such as staurosporine may prevent the phosphorylation state that is required for FLJ31485 activation or function. Similarly, compounds that influence the PI3K/AKT/mTOR pathway, like LY294002 and rapamycin, could potentially lead to decreased FLJ31485 activity by inhibiting the pathway's downstream effects on protein synthesis and cell survival, processes in which FLJ31485 might be implicated.
Additionally, the MAPK pathway, which can be affected by compounds such as U0126, SB203580, and PD98059, plays a critical role in transducing extracellular signals to cellular responses. Inhibition of this pathway could reduce the activity of FLJ31485 if it is a downstream effector. Furthermore, cellular energy metabolism and homeostasis are vital for protein function. Inhibitors like 2-Deoxy-D-glucose and WZB117 could lead to decreased FLJ31485 activity by limiting the energy supply or necessary substrates. Thapsigargin's role in disrupting calcium homeostasis may also inhibit FLJ31485 activity if it is regulated by calcium signaling.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent protein kinase inhibitor that can inhibit protein kinase C (PKC). If FLJ31485 is a kinase or regulated by PKC, staurosporine could decrease its activity by inhibiting PKC-mediated phosphorylation events that activate FLJ31485. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
This compound is a phosphoinositide 3-kinases (PI3K) inhibitor. If FLJ31485 operates downstream of PI3K or is regulated by AKT signaling, LY294002 could inhibit the pathway, leading to reduced FLJ31485 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
As an mTOR inhibitor, rapamycin could inhibit the mTOR pathway, which is involved in cell growth and proliferation. If FLJ31485 is involved in these processes, inhibition of mTOR could result in reduced activity of FLJ31485. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK. If FLJ31485 is activated by stress-related signaling through p38 MAPK, SB203580 could inhibit these signals, leading to a decrease in FLJ31485 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which could block the activation of ERK. If FLJ31485 is dependent on ERK signaling for its activity, inhibition by PD98059 would result in decreased FLJ31485 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. If FLJ31485 is degraded by the ubiquitin-proteasome system, inhibition of this system could lead to decreased levels of functional FLJ31485 due to accumulation of misfolded or dysfunctional proteins that would normally be degraded. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A is an immunosuppressant that inhibits calcineurin. If FLJ31485 activity is promoted by calcineurin through dephosphorylation of certain substrates, then inhibition of calcineurin would lead to reduced FLJ31485 activity. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
This glucose analog inhibits glycolysis by blocking hexokinase. If FLJ31485 requires energy from glycolysis for its activity, inhibition of glycolysis could indirectly reduce FLJ31485 activity by limiting energy supply. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $49.00 $124.00 $441.00 $828.00 | 4 | |
WZB117 is a glucose transporter 1 (GLUT1) inhibitor. If FLJ31485 is involved in pathways requiring high levels of glucose, such as in highly proliferative cells, inhibition of glucose uptake could indirectly decrease FLJ31485 activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor, leading to increased cytosolic calcium levels. If FLJ31485 is regulated by calcium signaling, disruption of calcium homeostasis could indirectly inhibit its activity. | ||||||